Acute tubular necrosis associated with mTOR inhibitor therapy: A real entity biopsy-proven

Hassane Izzedine, B. Escudier, P. Rouvier, V. Gueutin, A. Varga, R. Bahleda, J. C. Soria

    Résultats de recherche: Contribution à un journalArticleRevue par des pairs

    33 Citations (Scopus)

    Résumé

    Background: The protein kinase mTOR (mammalian target of rapamycin) is a critical regulator of cellular metabolism, growth, and proliferation. Inhibitors of mTOR have immunosuppressive and anti-cancer effects, but their effects on the progression of kidney disease are not fully understood. Their most common side-effects include stomatitis, rash, dyslipidemia, hyperglycemia, fatigue, and pneumonitis. However, to the best of our knowledge these agents have not been previously reported to cause severe acute kidney injury (AKI). Case presentation: We describe four cases of patients with cancer who developed AKI after starting mTOR inhibitor therapy. A kidney biopsy showed acute tubular necrosis (ATN) with prominent tubular dysfunction. Withdrawal of the drug leads to a rapid recovery in two cases. However, a fixed renal dysfunction was noted in the other two cases, one of which will remain dialysis-dependent. Such patients lead to a broad differential diagnosis of AKI including prerenal AKI, ATN, cancer-related GN, and drug-induced acute interstitial nephritis. Accurate history, physical examination, laboratory data, and kidney biopsy are highlighted in establishing the correct diagnosis in such patients. Conclusions: ATN have not been reported with mTOR inhibitor use. These cases demonstrated a potentially new and serious adverse consequence occurring with the use of an mTOR inhibitor, of which physicians need to be aware.

    langue originaleAnglais
    Pages (de - à)2421-2425
    Nombre de pages5
    journalAnnals of Oncology
    Volume24
    Numéro de publication9
    Les DOIs
    étatPublié - 1 janv. 2013

    Contient cette citation